Brind.

Madrigal Pharmaceuticals' Rezdiffra received authorization for MASH from the European Commission, prompting analyst price target increases.

6 reports, 2 independent Updated Sep 5
Gone quiet Reached 2 outlets in its first 24 hours
Reports
6
Developments
2
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Madrigal Pharmaceuticals' Rezdiffra received authorization for MASH from the European Commission, prompting analyst price target increases.

Who's involved

What this event is mainly about
Madrigal Pharmaceuticals (United States)Mash

How it developed

Newest first. Tap a step to see who reported it.
  1. Rezdiffra is authorized for MASH by the European Commission, leading to analyst price target increases.1 source
  2. EC granted conditional marketing authorization for Madrigal's Rezdiffra for MASH.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyTD Cowen Sees Greater Upside in Madrigal (MDGL) Following Recent Rezdiffra Approval Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the most shorted stocks right now. On August 25, TD Cowen ana
  • GlobeNewswireMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL),
  • Insider MonkeyLeerink Partners Maintains a Buy on Madrigal Pharmaceuticals (MDGL), Here’s Why Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds.
  • GlobeNewswireMadrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis Rezdiffra is the first and only medication approved for p
  • GlobeNewswireMadrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 million As of June 30, 2025, more
  • Unknown outlet